[go: up one dir, main page]

NO20032902L - Medisinske preparater som inneholder aspirin - Google Patents

Medisinske preparater som inneholder aspirin

Info

Publication number
NO20032902L
NO20032902L NO20032902A NO20032902A NO20032902L NO 20032902 L NO20032902 L NO 20032902L NO 20032902 A NO20032902 A NO 20032902A NO 20032902 A NO20032902 A NO 20032902A NO 20032902 L NO20032902 L NO 20032902L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
aspirin
containing aspirin
medications containing
äeffectü
Prior art date
Application number
NO20032902A
Other languages
English (en)
Other versions
NO20032902D0 (no
Inventor
Fumitoshi Asai
Atsuhiro Sugidachi
Taketoshi Ogawa
Teruhiko Inoue
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18858878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032902(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ube Industries filed Critical Ube Industries
Publication of NO20032902D0 publication Critical patent/NO20032902D0/no
Publication of NO20032902L publication Critical patent/NO20032902L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20032902A 2000-12-25 2003-06-24 Medisinske preparater som inneholder aspirin NO20032902L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000392983 2000-12-25
PCT/JP2001/011201 WO2002051412A1 (en) 2000-12-25 2001-12-20 Medicinal compositions containing aspirin

Publications (2)

Publication Number Publication Date
NO20032902D0 NO20032902D0 (no) 2003-06-24
NO20032902L true NO20032902L (no) 2003-06-24

Family

ID=18858878

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032902A NO20032902L (no) 2000-12-25 2003-06-24 Medisinske preparater som inneholder aspirin

Country Status (25)

Country Link
US (3) US20040024013A1 (no)
EP (1) EP1350511B1 (no)
KR (1) KR100692934B1 (no)
CN (1) CN100341506C (no)
AT (1) ATE407675T1 (no)
AU (1) AU2002217464B2 (no)
BR (1) BR0116531A (no)
CA (1) CA2432644C (no)
CY (1) CY1108626T1 (no)
CZ (1) CZ297570B6 (no)
DE (1) DE60135780D1 (no)
DK (1) DK1350511T3 (no)
ES (1) ES2311498T3 (no)
HU (1) HUP0400644A3 (no)
IL (2) IL156456A0 (no)
MX (1) MXPA03005770A (no)
NO (1) NO20032902L (no)
NZ (1) NZ526540A (no)
PL (1) PL206138B1 (no)
PT (1) PT1350511E (no)
RU (1) RU2262933C2 (no)
SK (1) SK287972B6 (no)
TW (1) TWI293249B (no)
WO (1) WO2002051412A1 (no)
ZA (1) ZA200304878B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1728794B1 (en) * 2000-07-06 2008-06-18 Daiichi Sankyo Company, Limited Maleate addition salt of hydropyridine derivatives
MXPA03005770A (es) 2000-12-25 2003-09-10 Sankyo Co Composiciones medicinales que contienen aspirina.
US20060217351A1 (en) * 2003-05-05 2006-09-28 Brandt John T Method for treating cardiovascular diseases
CN100488163C (zh) * 2005-01-19 2009-05-13 华为技术有限公司 组播业务处理方法和系统
MX2007015430A (es) * 2005-06-17 2008-02-21 Lilly Co Eli Regimen de dosificacion para prasugrel.
DE102005029612A1 (de) * 2005-06-23 2007-01-04 Hochschule Bremen Vorrichtung zum Erzeugen eines Panoramabildes
US20080214599A1 (en) * 2005-08-19 2008-09-04 John Thomas Brandt Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
EP2145890B1 (en) * 2006-06-27 2012-08-01 Sandoz AG Crystallization of hydrohalides of pharmaceutical compounds
KR101442862B1 (ko) * 2006-12-07 2014-09-22 다이이찌 산쿄 가부시키가이샤 만니톨 또는 유당을 함유하는 고형 제제
KR101647842B1 (ko) * 2006-12-07 2016-08-11 다이이찌 산쿄 가부시키가이샤 저장 안정성이 개선된 의약 조성물
CN101594863B (zh) * 2006-12-07 2011-12-07 第一三共株式会社 具有改进稳定性的涂膜制剂
BRPI0719529B8 (pt) * 2006-12-07 2021-05-25 Daiichi Sankyo Co Ltd método para produzir uma preparação sólida
EP2100610A4 (en) * 2006-12-07 2009-12-02 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE
AU2008222000B2 (en) * 2007-03-02 2012-06-14 Daiichi Sankyo Company, Limited Process for production of prasugrel hydrochloride having high purity
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
CN101177430A (zh) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 氢化吡啶衍生物及其盐的制备方法
WO2010015144A1 (zh) 2008-08-02 2010-02-11 鲁南制药集团股份有限公司 普拉格雷硫酸氢盐及其药物组合物和应用
US20090281136A1 (en) * 2008-05-08 2009-11-12 Sandeep Mhetre Prasugrel pharmaceutical formulations
KR101912709B1 (ko) * 2009-05-13 2018-10-30 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
CN102228691A (zh) * 2011-06-29 2011-11-02 北京阜康仁生物制药科技有限公司 阿司匹林和一种抗血小板药物的药物组合物
US9757395B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
DK3107548T3 (da) 2014-02-20 2022-07-18 Otitopic Inc Tørpulverformuleringer til inhalation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2890240A (en) * 1956-03-28 1959-06-09 Monsanto Chemicals Aspirin crystallisation
US3235583A (en) * 1964-07-22 1966-02-15 Norwich Pharma Co Preparation of aspirin
US3890240A (en) * 1966-11-28 1975-06-17 Pitney Bowes Inc Toner compositions and methods for their preparation
FR2215948B1 (no) 1973-02-01 1976-05-14 Centre Etd Ind Pharma
FR2345150A2 (fr) 1975-08-06 1977-10-21 Centre Etd Ind Pharma Nouveaux derives de la thienopyridine, et leur application
FR2307538A1 (fr) * 1975-04-18 1976-11-12 Centre Etd Ind Pharma Nouveau medicament anti-agregant plaquettaire
FR2312247A1 (fr) 1975-05-30 1976-12-24 Parcor Derives de la thieno-pyridine, leur procede de preparation et leurs applications
FR2358150A1 (fr) * 1976-07-13 1978-02-10 Parcor Nouvelles thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application
FR2376860A1 (fr) * 1977-01-07 1978-08-04 Parcor Tetrahydro-4,5,6,7 thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application therapeutique
GB1576511A (en) * 1977-03-29 1980-10-08 Parcor Thieno(2,3 - c) and (3,2 - c) pyridines process for their preparation and therapeutic applications thereof
GB2038625B (en) * 1978-12-29 1983-01-12 Parcor Therapeutic composition having an antithrombotic and antiblood-platelet-aggregating activity
CA1147658A (en) 1980-01-03 1983-06-07 Edouard Panak Therapeutic compositions having antithrombotic and anti-blood-platelet- aggregating activity
US4400384A (en) * 1980-10-06 1983-08-23 Sanofi, S.A. 5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate and other novel salts thereof
US4321266A (en) * 1980-10-06 1982-03-23 Sanofi 5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-C] pyridine
FR2495156A1 (fr) * 1980-11-28 1982-06-04 Sanofi Sa Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique
FR2528848A1 (fr) * 1982-06-16 1983-12-23 Sanofi Sa Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) * 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
FR2596392B1 (fr) 1986-03-27 1988-08-05 Sanofi Sa Derives de l'acide a-(hydroxy-3 oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenylacetique, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2597102B1 (fr) 1986-04-14 1988-08-26 Sanofi Sa Derives de l'acide a-(hydroxy-7 tetrahydro-4,5,6,7 thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
US5401730A (en) * 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
ZA926784B (en) * 1991-09-09 1993-03-29 Sankyo Co Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation.
CA2087743C (en) 1992-02-06 1999-04-27 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
EP0573975A1 (en) 1992-06-08 1993-12-15 Fuji Photo Film Co., Ltd. 2-alkoxycarbonyl-5-o-chlorobenzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine derivative and process for producing the same
EP0641770B1 (en) 1993-03-17 1998-05-13 Meiji Seika Kabushiki Kaisha Novel compound with platelet aggregation inhibitor activity
JPH06271582A (ja) 1993-03-18 1994-09-27 Fuji Photo Film Co Ltd ４，５，６，７−テトラヒドロチエノ〔３，２−ｃ〕ピリジン誘導体の製造方法
EP0785205B1 (en) * 1994-10-07 2002-04-17 Ube Industries, Ltd. 2-silyloxytetrahydrothienopyridine, salt thereof, and process for producing the same
JP3564791B2 (ja) 1995-04-21 2004-09-15 宇部興産株式会社 α−アミノケトン類の製造方法
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
IT1306980B1 (it) 1999-01-13 2001-10-11 Magneti Marelli Spa Gruppo motore-cambio di velocita', in particolare per motocicli.
CN1108798C (zh) * 1999-01-26 2003-05-21 广东药学院 一种治疗、预防血栓形成及中风的复方制剂及其制备方法
JP2000266780A (ja) 1999-03-18 2000-09-29 Matsushita Electric Ind Co Ltd プローブカードとそれを用いた検査装置
IT1311923B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
FR2792836B3 (fr) 1999-04-30 2001-07-27 Sanofi Sa Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1728794B1 (en) * 2000-07-06 2008-06-18 Daiichi Sankyo Company, Limited Maleate addition salt of hydropyridine derivatives
JP4001199B2 (ja) 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
US6642252B2 (en) * 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
MXPA03005770A (es) 2000-12-25 2003-09-10 Sankyo Co Composiciones medicinales que contienen aspirina.
US6670386B2 (en) * 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
JP2007513889A (ja) * 2004-09-21 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド 結晶性クロピドグレル臭酸塩及びその調製方法
DE112009000268T5 (de) * 2008-02-06 2011-06-01 Helm Ag Prasugrel-Salze mit verbesserten Eigenschaften
DE202008003557U1 (de) 2008-03-13 2008-06-05 Riela - Getreidetechnik Karl-Heinz Knoop E.K. Schubwendetrockner mit Feuchte-Messeinrichtung
EP2112155B1 (en) 2008-04-25 2010-09-29 Sandoz AG Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
GB2469883A (en) 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
HU3745U (en) 2009-10-01 2010-03-29 Laszlo Borzan Disk guide device for target disk launcher or bowler equipments

Also Published As

Publication number Publication date
CZ20031660A3 (cs) 2003-12-17
KR20030065558A (ko) 2003-08-06
HUP0400644A2 (hu) 2004-06-28
ES2311498T3 (es) 2009-02-16
US20040024013A1 (en) 2004-02-05
WO2002051412A1 (en) 2002-07-04
MXPA03005770A (es) 2003-09-10
BR0116531A (pt) 2004-02-25
DK1350511T3 (da) 2009-01-05
CA2432644C (en) 2013-07-23
US8404703B2 (en) 2013-03-26
NZ526540A (en) 2004-11-26
EP1350511A4 (en) 2004-06-23
PL363183A1 (en) 2004-11-15
SK287972B6 (sk) 2012-08-06
ATE407675T1 (de) 2008-09-15
SK7542003A3 (en) 2003-12-02
KR100692934B1 (ko) 2007-03-12
PT1350511E (pt) 2008-10-28
ZA200304878B (en) 2004-08-10
AU2002217464B2 (en) 2004-12-16
US20070010499A1 (en) 2007-01-11
US8569325B2 (en) 2013-10-29
NO20032902D0 (no) 2003-06-24
HUP0400644A3 (en) 2009-06-29
IL156456A (en) 2006-12-10
CN100341506C (zh) 2007-10-10
PL206138B1 (pl) 2010-07-30
RU2262933C2 (ru) 2005-10-27
EP1350511B1 (en) 2008-09-10
DE60135780D1 (de) 2008-10-23
US20080108589A1 (en) 2008-05-08
HK1056118A1 (en) 2004-02-06
CZ297570B6 (cs) 2007-02-07
TWI293249B (en) 2008-02-11
CA2432644A1 (en) 2002-07-04
IL156456A0 (en) 2004-01-04
CY1108626T1 (el) 2014-04-09
EP1350511A1 (en) 2003-10-08
CN1491109A (zh) 2004-04-21

Similar Documents

Publication Publication Date Title
NO20032902D0 (no) Medisinske preparater som inneholder aspirin
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
NO20032233L (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
DK0816376T3 (da) Thrombininhibitorer som antikoagulante midler
NO20034612L (no) 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
NO20034149L (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
EP1734041A3 (en) Platelet ADP receptor inhibitors
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
CA2481848A1 (en) Active ingredient particles carrying clopidogrel or a salt thereof, their use and method of preparation
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
EP1303271A4 (en) Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
NO950297D0 (no) Prolinamidderivater
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
DK0920421T3 (da) Isoxazolinderivater anvendelige som antimikrobielle midler
ATE395071T1 (de) Pharmazeutische zubereitungen zur angiogenese- therapie
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
DE60029242D1 (de) Arzneien zur begleitenden behandlung von glaukomen
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
DE69819539D1 (de) Antithrombotische mittel
SE0002729D0 (sv) Novel compound form
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
EP1065200A4 (en) Aminoisoquinoline DERIVATIVES
WO2002078633A8 (en) Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia

Legal Events

Date Code Title Description
BDEC Board of appeal decision

Free format text: KLAGEN FORKASTES. KLAGENEMNDAS AVGJOERELSE ETTER KLAGE PA INNSIGELSESAVGJOERELSE

Filing date: 20160412

Effective date: 20170206